Endpoints Peer Review: Biogen Searches for a CEO, Roivant Selects Srini Ramanathan as CDO

In the latest Endpoints Peer Review, Biogen looks for a new head to replace its CEO, Michel Vounatsos. The company intends to replace Vounatsos before March 2023. In other news, Roivant has announced their new chief development officer, Srini Ramanathan, former senior vice president of R&D Sciences at Horizon Therapeutics. This week’s issue also covers news from OncoSec.

According to Alex Hoffman and Kathy Wong of Endpoints News, “Partnering with Merck on a Keytruda–Tavo combo, OncoSec has found someone to fill the top spot. Robert Arch has taken over as president and CEO after Brian Leuthner bridged the gap as interim chief when Dan O’Connor stepped down. “

Read more by clicking here.

(Source: AJMC, May 4^th, 2022)